GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Medios AG (LTS:0QB4) » Definitions » COGS-to-Revenue

Medios AG (LTS:0QB4) COGS-to-Revenue : 0.94 (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Medios AG COGS-to-Revenue?

Medios AG's Cost of Goods Sold for the three months ended in Mar. 2024 was €430 Mil. Its Revenue for the three months ended in Mar. 2024 was €456 Mil.

Medios AG's COGS to Revenue for the three months ended in Mar. 2024 was 0.94.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Medios AG's Gross Margin % for the three months ended in Mar. 2024 was 5.79%.


Medios AG COGS-to-Revenue Historical Data

The historical data trend for Medios AG's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medios AG COGS-to-Revenue Chart

Medios AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.93 0.94 0.95 0.93 0.94

Medios AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.94 0.94 0.94 0.94 0.94

Medios AG COGS-to-Revenue Calculation

Medios AG's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1675.124 / 1784.703
=0.94

Medios AG's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=429.802 / 456.224
=0.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medios AG  (LTS:0QB4) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Medios AG's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 429.802 / 456.224
=5.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Medios AG COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Medios AG's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Medios AG (LTS:0QB4) Business Description

Address
Friedrichstrasse 113a, Berlin, DEU, 10117
Medios AG is engaged as a wholesaler for pharmaceutical medicinal products. The operating segments of the company includes provision of medicinal products which focuses on pharmaceutical medicinal products; Patient-specific therapies comprise the manufacture of medications.

Medios AG (LTS:0QB4) Headlines

No Headlines